Investigational Tx Granted Orphan Drug Status for Spinocerebellar Ataxia

No treatments currently exist for this rare, debilitating neurodegenerative disorder
No treatments currently exist for this rare, debilitating neurodegenerative disorder

Portage Biotech announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to Biohaven's investigational agent BHV-4157 for the treatment of Spinocerebellar Ataxia (SCA).

Spinocerebellar ataxia, a rare, debilitating neurodegenerative disorder, currently has no approved pharmacological treatment, only supportive therapy. 

Related Articles

Biohaven intends to initiate a randomized clinical trial for BHV-4157 in 120 patients with hereditary SCA before the end of 2016. Results from this trial are expected to support a New Drug Application (NDA) for BHV-4157 in SCA.

BHV-4157 is a novel glutamate-modulating agent.

For more information visit Portagebiotech.com or Biohavenpharma.com.

Loading links....